National Cancer Institute

C-Path and CDISC launch CFAST

Friday, September 14, 2012 12:35 PM

The Clinical Data Interchange Standards Consortium (CDISC), a global non-profit charitable organization, and Critical Path Institute (C-Path), a Tucson, Ariz.-based non-profit organization committed to improving human health and well-being, have launched their joint Coalition For Accelerating Standards and Therapies (CFAST), a follow-up to the partnership agreement signed earlier this year.

More... »

Recipients of 2012 SAFE-Biopharma Digi Award named

Monday, April 30, 2012 04:52 PM

Recipients have been selected for the 2012 SAFE-BioPharma Digi Award, recognizing innovative uses of the global SAFE-BioPharma digital identity and digital signature standard and the institutions and individuals contributing to broader understanding of its benefits. Recipients included: Astellas, Bristol-Myers Squibb and representatives of two U.S. government entities.

More... »

Syndax initiates phase I/II study in metastatic breast cancer

Monday, April 9, 2012 04:42 PM

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company based in Waltham, Mass., has initiated a phase I/II study combining its lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

More... »

SAFE-BioPharma named Computerworld Laureate

Monday, March 26, 2012 03:49 PM

SAFE-BioPharma, the global digital identity and digital signature standard for the life sciences and healthcare sectors, has been named a 2012 Computerworld Laureate.

More... »

Celtic launches $50 million antibody drug conjugates company

Monday, March 26, 2012 12:19 PM

Celtic Therapeutics Management, a global private equity firm focused on novel therapeutic product candidates, has announced a significant commitment to Antibody-Drug-Conjugate (ADC) products with the launch of a new Lausanne, Switzerland-based company, ADC Therapeutics Sarl.

More... »

Metabolomx awarded $1.14 million grant from NCI

Monday, October 24, 2011 01:34 PM

Metabolomx, a diagnostic company focused on breath analysis for the detection of cancer, has been awarded a Small Business Innovation Research (SBIR) contract by the National Cancer Institute (NCI). The $1.14 million combined phase I/II Fast-Track contract will support the research and development of Metabolomx' sensor array system to detect lung cancer.

More... »

Beaumont Health System launches national breast cancer study

Tuesday, September 27, 2011 11:23 AM

Beaumont Health System has launched national research of accelerated whole breast radiation treatment for women with early-stage breast cancer. The study, RTOG 1005, was developed by the Radiation Therapy Oncology Group, a cancer therapy research cooperative group funded by the National Cancer Institute at the National Institutes of Health, part of the U.S. Department of Health and Human Services.

More... »

EGEN, Nanotechnology Characterization Lab collaborate in brain cancer research

Tuesday, September 27, 2011 11:09 AM

EGEN is collaborating with the National Cancer Institute'sNanotechnology Characterization Laboratory in Frederick, Md., to accelerate human clinical testing of a nanotechnology-based gene therapy for brain cancer.

More... »

Delcath’s phase II liver cancer trial shows promising results

Monday, August 22, 2011 12:45 PM

Delcath Systems has reported encouraging top-line results from the hepatobiliary cohort of the phase II clinical trial of the Delcath chemosaturation system with melphalan in the treatment of patients with unresectable liver cancer.

More... »

BU professor fabricates data in two published experiments

Wednesday, August 10, 2011 11:43 AM

A cancer researcher and assistant professor at the Boston University School of Medicine Cancer Research Center fabricated data in two papers published in scientific journals, federal authorities announced, according to a report by the Boston Globe.

More... »